BEAM THERAPEUTICS INC (BEAM) Stock Price & Overview
NASDAQ:BEAM • US07373V1052
Current stock price
The current stock price of BEAM is 24.63 USD. Today BEAM is down by -2.15%. In the past month the price decreased by -10.73%. In the past year, price increased by 5.71%.
BEAM Key Statistics
- Market Cap
- 2.509B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.44
- Dividend Yield
- N/A
BEAM Stock Performance
BEAM Stock Chart
BEAM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BEAM. When comparing the yearly performance of all stocks, BEAM turns out to be only a medium performer in the overall market: it outperformed 44.17% of all stocks.
BEAM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BEAM. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability.
BEAM Earnings
On February 24, 2026 BEAM reported an EPS of -0.1 and a revenue of 114.11M. The company beat EPS expectations (89.82% surprise) and beat revenue expectations (790.22% surprise).
BEAM Forecast & Estimates
25 analysts have analysed BEAM and the average price target is 49.1 USD. This implies a price increase of 99.35% is expected in the next year compared to the current price of 24.63.
For the next year, analysts expect an EPS growth of -35.55% and a revenue growth 23.62% for BEAM
BEAM Groups
Sector & Classification
BEAM Financial Highlights
Over the last trailing twelve months BEAM reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 24.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.4% | ||
| ROE | -6.46% | ||
| Debt/Equity | 0 |
BEAM Ownership
BEAM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BEAM
Company Profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 511 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Company Info
IPO: 2020-02-06
BEAM THERAPEUTICS INC
238 Main Street
Cambridge MASSACHUSETTS 02139 US
CEO: John Evans
Employees: 511
Phone: 13026587581
BEAM THERAPEUTICS INC / BEAM FAQ
What does BEAM THERAPEUTICS INC do?
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 511 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Can you provide the latest stock price for BEAM THERAPEUTICS INC?
The current stock price of BEAM is 24.63 USD. The price decreased by -2.15% in the last trading session.
What is the dividend status of BEAM THERAPEUTICS INC?
BEAM does not pay a dividend.
What is the ChartMill technical and fundamental rating of BEAM stock?
BEAM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for BEAM THERAPEUTICS INC?
BEAM THERAPEUTICS INC (BEAM) currently has 511 employees.
What is the next earnings date for BEAM stock?
BEAM THERAPEUTICS INC (BEAM) will report earnings on 2026-05-04.
Can you provide the ownership details for BEAM stock?
You can find the ownership structure of BEAM THERAPEUTICS INC (BEAM) on the Ownership tab.